Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy
- 23 February 2016
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 173 (5), 663-670
- https://doi.org/10.1111/bjh.13955
Abstract
Langerhans cell histiocytosis (LCH) is a rare disease, affecting subjects of any age, with extremely variable clinical manifestations. Although most patients with LCH have localized disease, requiring local or even no therapy, those patients with disseminated, 'multi-system' disease require specific therapy because they may be at risk for morbidity or even mortality. The current standard of care has developed empirically, based mainly on the experience of treating children with leukaemia and other haemo-proliferative disorders. At the time of writing, the combined use of vinblastine and prednisone remains the standard of care for children with multi-system LCH. The combination of cytarabine and cladribine is the current standard for second-line therapy of refractory cases with vital organ dysfunction. Recent advances in the knowledge of the pathogenesis of LCH may support a change in treatment strategy. Evidence of mutations that aberrantly activate RAF/MEK/ERK signalling in over two thirds of patients with LCH may direct a target therapy strategy. Vemurafenib, a small molecule widely used in the treatment of melanoma, is the main candidate for testing in prospective trials for patients with evidence of BRAF(V) (600E) mutation on lesional tissue. Additional molecules, including the recently approved trametinib, could follow. Identification of mutations in other genes in the remaining multisystem LCH cases could contribute to define a scenario in which target therapy becomes the main therapeutic choice in this intriguing disorder. However, because the long-term risks and benefits of these agents in children are unknown, and other effective treatments exist for many LCH patients, the optimal indications for administering a tyrosine kinase inhibitor to children is an open question.This publication has 65 references indexed in Scilit:
- Pulmonary langerhans cell histiocytosisOrphanet Journal of Rare Diseases, 2012
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010
- Reactivations in Multisystem Langerhans Cell Histiocytosis: Data of the International LCH RegistryThe Journal of Pediatrics, 2008
- Clofarabine in refractory Langerhans cell histiocytosisPediatric Blood & Cancer, 2008
- Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosisEuropean Journal of Cancer, 2006
- Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunctionEuropean Journal of Cancer, 2005
- Intralesional infiltration of corticosteroids in the treatment of localised langerhans’ cell histiocytosis of the mandible: Report of known cases and three new casesInternational Journal of Oral & Maxillofacial Surgery, 2005
- Treatment of Multisystem Langerhans Cell Histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 StudiesKlinische Padiatrie, 2000
- VP-16 and the treatment of histiocytosisEuropean Journal of Pediatrics, 1994
- Topical nitrogen mustard: An effective treatment for cutaneous Langerhans cell histiocytosisThe Journal of Pediatrics, 1991